Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

  • Discontinued
  • GID-TA10186

Documents

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators